Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Morgentaler
Abraham
A
D001378:Azasteroids / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D000068538:Dutasteride; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
D001378:Azasteroids; D015415:Biomarkers; D042944:Cholestenone 5 alpha-Reductase; D017430:Prostate-Specific Antigen; D000068538:Dutasteride